Pluristem Therapeutics, Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company’s first planned product, PLX-I, targets a $3 billion annual market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT). Pluristem also believes its PLacental eXpanded (PLX) cells will be helpful for a variety of other indication, including as a help to patients afflicted with Peripheral Artery Disease (PAD) with critical limb ischemia (CLI).

Gamida Cell employs proprietary technologies for expansion of hematopoietic progenitor cells (HPC). These technologies utilize small molecules to modulate differentiation of cultured cells. The safety of the first developed technology was demonstrated in the clinic in a Phase I/II study.

Cell Cure’s scientific team, headed by Prof. Reubinoff, is a leader in the race for the development of methods for directing hESCs to develop into neurons capable of integrating into the brain and producing dopamine. They have already demonstrated partial functional recovery of Parkinsonian rats following the transplantation of non-committed hESC-derived neural precursors.

Proneuron Biotechnologies, a Delaware company, is in advanced stages of clinical development in a number of attractive neurological markets. Proneuron is the first company to harness the power of the body’s own immune system for the treatment of debilitating central nervous system (CNS) disorders.